Overcoming Deadly Diseases


A new class of selective therapies demonstrating potential against gliomas, leukemia and other cancers

TEMBEXA® (brincidofovir)

The first antiviral approved for the treatment of smallpox in all age groups

Improving and Extending Lives

Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.  Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.

TEMBEXA® Transaction

Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

More about TEMBEXA® Transaction

2021 SNO Annual Meeting

Chimerix’s latest efficacy data for ONC201 will be presented at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting.

SNO 2021 Details